Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 150.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 150.
STALEVO 100 vs STALEVO 150
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
None Documented
None Documented
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent